Advertisement

Reactions Weekly

, Volume 1779, Issue 1, pp 60–60 | Cite as

Carmustine polifeprosan 20 wafer/isotretinoin/temozolomide

Second primary cancers: 6 case reports
Case report
  • 60 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study of 155 patients diagnosed with glioblastoma between 1 January 1998 and 8 February 2010, 6 patients (4 men and 2 women) aged 30−69 years were described, who developed various second primary cancers following treatment with temozolomide, isotretinoin or carmustine polifeprosan 20 wafer for glioblastoma (GBM) [routes not stated; not all dosages, times to reactions onsets and outcomes stated].

A 69-year-old man developed systemic leukaemia following treatment with temozolomide: The man, who was a long-term survivor in the setting of GBM (GBM diagnosed at the age of 61 years), underwent a gross total resection (GTR) followed by external-beam radiation with adjuvant temozolomide. He completed 12 months of adjuvant temozolomide followed by serial imaging....

Reference

  1. Kim J-Y, et al. Second primary cancers in long-term survivors of glioblastoma. Neuro-Oncology Practice 6: 386-391, No. 5, Oct 2019. Available from: URL: http://doi.org/10.1093/nop/npz001 - USACrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations